Myelofibrosis Clinical Trials in New York, New York
17 recruitingNew York, New York
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 1Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198
Recruiting
Phase 2
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Myelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
National Cancer Institute (NCI)62 enrolled30 locationsNCT06661915
Recruiting
Phase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 1Phase 2
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Myelofibrosis
Memorial Sloan Kettering Cancer Center37 enrolled9 locationsNCT06773195
Recruiting
Phase 1
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Primary Myelofibrosis
Ajax Therapeutics, Inc.76 enrolled16 locationsNCT06343805
Recruiting
Phase 2
Study of Canakinumab in Patients With Myelofibrosis
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas14 enrolled8 locationsNCT05467800
Recruiting
Phase 2
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 2
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
AMLMDSHLH+6 more
Memorial Sloan Kettering Cancer Center31 enrolled1 locationNCT04644016
Recruiting
Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting
Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Karyopharm Therapeutics Inc58 enrolled70 locationsNCT05980806
Recruiting
Phase 2
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai26 enrolled9 locationsNCT05835466
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Myelofibrosis
Geron Corporation36 enrolled8 locationsNCT05371964
Recruiting
Phase 1
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Myelofibrosis Due to and Following Polycythemia Vera
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT05714072
Recruiting
Phase 3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisMF+2 more
Kartos Therapeutics, Inc.600 enrolled215 locationsNCT06479135
Recruiting
Phase 1
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Myelofibrosis
Cellenkos, Inc.24 enrolled4 locationsNCT05423691
Recruiting
Phase 1
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
MyelofibrosisEssential ThrombocythemiaMPN
Marina Kremyanskaya10 enrolled1 locationNCT05025488